Skip to main content
Premium Trial:

Request an Annual Quote

TM Bioscience Issues Warrants for $14.4M

Premium

TORONTO--TM Biosciences announced that is has agreed, subject to regulatory approval, to issue up to 18 million special warrants on a private placement basis at 80 cents per special warrant, for aggregate gross proceeds of $14.4 million. The issue and sale of more than 12 million of the special warrants for proceeds of $10.1 million will be by way of a private placement underwritten by Yorkton Securities. The remaining warrants will be purchased by Canadian Medical Discoveries Fund for proceeds of $4.3 million. TM designs, develops, and commercializes DNA products for medical diagnostics, therapeutics, biochips, functional genomics, and bioinformatics.

Filed under

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.